融捷健康(300247) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was CNY 215,155,627.19, down 30.34% year-on-year, with a year-to-date total of CNY 723,351,740.70, a decrease of 4.43%[7] - Net profit attributable to shareholders was CNY 14,429,464.39, a decline of 8.27% compared to the same period last year, with a year-to-date total of CNY 45,490,852.41, down 9.36%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 8,891,351.67, a decrease of 37.11% year-on-year[7] - The basic earnings per share for the reporting period was CNY 0.0179, down 8.21% compared to the same period last year[7] - The weighted average return on equity was 0.59%, a decrease of 0.08% compared to the previous year[7] - Total operating revenue for the third quarter was CNY 215,155,627.19, a decrease from CNY 308,876,812.69 in the previous period[40] - Total operating costs amounted to CNY 209,089,339.10, down from CNY 291,708,757.61 year-over-year[40] - Net profit for the period was CNY 14,285,471.47, slightly down from CNY 14,673,470.33 in the same period last year[42] - The company reported a total comprehensive income of CNY 18,881,796.44, compared to CNY 21,304,396.29 in the previous year[43] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,946,079,402.13, a decrease of 4.02% compared to the end of the previous year[7] - Total assets decreased from CNY 3,069,523,158.22 at the beginning of the period to CNY 2,946,079,402.13 by the end of the period, a decline of approximately 4.01%[32] - Current assets decreased from CNY 1,305,778,038.37 to CNY 1,159,521,260.29, representing a reduction of about 11.21%[33] - Total liabilities decreased from CNY 612,238,862.53 to CNY 462,131,802.52, a reduction of about 24.5%[35] - Current liabilities decreased from CNY 569,331,454.27 to CNY 435,170,569.61, a decline of approximately 23.5%[35] - Non-current liabilities decreased from CNY 42,907,408.26 to CNY 26,961,232.91, a reduction of about 37.2%[35] - Total equity increased from CNY 2,457,284,295.69 to CNY 2,483,947,599.61, an increase of approximately 1.09%[35] Cash Flow - The net cash flow from operating activities was CNY -56,710,951.59, representing a significant decline of 4,188.47% year-on-year[7] - The company did not receive any investment cash during the reporting period, resulting in a 100% decrease in cash flow from financing activities[20] - Cash and cash equivalents decreased by 63.27% compared to the beginning of the year, mainly due to the purchase of financial products and operational payments[18] - The net cash flow from investment activities was -¥92,682,564.06, compared to -¥35,620,927.54 in the previous period, indicating a significant increase in cash outflow[57] - The net cash flow from financing activities was -¥59,689,319.51, slightly worse than -¥58,464,852.89 from the previous period[57] - The total cash and cash equivalents at the end of the period decreased to ¥119,321,927.39 from ¥284,737,618.14 in the previous period[58] - Operating cash inflow totaled ¥108,043,311.51, down from ¥183,207,155.03 in the previous period, reflecting a decline in operational performance[59] - The net cash flow from operating activities was -¥12,603,212.99, a significant drop from a positive cash flow of ¥6,825,292.58 in the previous period[59] - Cash received from sales of goods and services was ¥65,180,015.58, down from ¥115,760,411.22 in the previous period, indicating reduced sales performance[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,860[11] - The largest shareholder, Jin Daoming, held 10.83% of the shares, amounting to 87,138,800 shares, with a portion pledged[11] - The company transferred a total of 40.8 million shares (5.07% of total shares) to Rongjie Group at a price of RMB 7.0 per share, totaling RMB 285.6 million[23] - The actual controller of the company changed to Rongjie Group after the share transfer[23] Investment and R&D - The company reported a government subsidy of CNY 10,405,308.32 during the year[8] - Research and development expenses increased to CNY 14,774,467.47, up from CNY 9,223,286.70 year-over-year, indicating a focus on innovation[40] - Investment income increased by 45.02% compared to the same period last year, mainly due to increased investment income from joint ventures and associates[19] - The company achieved an investment income of CNY 3,872,463.67, compared to CNY 1,289,178.93 in the previous period, reflecting improved performance in joint ventures[42] - The company reported a significant increase in investment income from joint ventures, rising to ¥11,943,735.71 from ¥2,110,349.74, an increase of approximately 466.5%[54]